Summers RW, Switz DM, Sessions Jr. JT, et al. National Cooperative Crohn's Disease Study : Results of drug treatment. Gastroenterology 1979 ; 77 : 847-69.
Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn 's Disease Study : Results of drug treatment. Gastroenterology 1984 ; 86 : 249-66.
Modigliani R, Mary JY, Simon JF, et al. Clinical, biological and endoscopic picture of attacks of Crohn 's disease : Evolution on prednisone. Gastroenterology 1990 ; 98 : 811-8.
Brignola C, de Simone G, Lannone I, et al. Influence of steroid treatment duration in patients with active Crohn 's disease. Agents actions. Special conference issue, 1992 ; C90-C2.
Landi B, N'Guyen Anh T, Cortot A, et al. Endoscopic monitoring of Crohn's disease treatment : A prospective randomized clinical trial. Gastroenterology 1992 ; 102 : 1647-53.
Brignola C, Iannone P, Belloli C, et al. Prediction of relapse in patients with Crohn 's disease in remission : A simplified index using laboratory tests, enhanced by clinical characteristics. Eur J Gastroenterol Hepato 1994 ; 6 : 955-61.
Louis E, Belaiche J, Van Kemseke C, et al. Soluble interleukin-2 receptor in Crohn 's disease. Assessment of disease activity and prediction of relapse. Dig Dis Sci 1995 ; 40 : 1750-6.
Louis E, Belaiche J, Van Kemseke C, et al. Crohn 's disease relapse by interleukin-6 serum level. Eur J Gastroenterol hepatol (à paraître)
Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in Crohn 's disease with steroid-induced remission : Effect on steroid withdrawal and remission maintenance. Gastroenterology 1996 ; 110 : 688-93.
Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn 's disease. Gastroenteroloy 1993 ; 105 : 367-72.
Lerebours E, Galmiche JP, Fouin-Fortunet H, et al. Etude de l'utilité d'une corticothérapie au cours des poussées aiguës de maladie de Crohn traitées par alimentation parentérale. Gastroenterol Clin Biol 1982 ; 6 : 1450-5.
Feliner JB, Adler DJ, Korelitz BI. The safety of corticosteroid therapy in Crohn 's disease with an abdominal mass. Am J Gastroenterol 1991 ; 86 : 1450-5.
Vakil N, Sparberg GM. Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology 1989 ; 96 : 62-7.
Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn 's disease. N Engl J Med 1994 ; 331 : 836-41.
Gravi V, Caesar A, Audus T, et al. Dose-finding study with oral budesonide in patients with active Crohn 's ileocolitis. Gastroenterology 1997 ; 112 (Suppl. 4) : A 986.
Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn 's disease. N Engl J Med 1994 ; 331 : 842-5.
Campieri M, Ferguson A, Doe W, et al. Oral budesonide competes favourably with prednisolime in active Crohn 's disease. Gastroenterology 1995 ; 108 (Suppl. 4) : A 790.
Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn 's disease : Result of a 16-week trial. Gastroenterology 1993 ; 104 : 1293-301.
Thomsen OO, Cortot A, Jewell D, et al. Budesonide CIR is more effective than mesalazine in active Crohn 's disease. A 16 week, international randomized double-blind multicentrique trial. Gastroenterology 1997 ; 112 (Suppl. 4) : A 1104.
